Commons, Marty

Alpelisib plus fulvestrant showed activity in PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor progression, with 6-month progression-free survival at 53.8% and manageable toxicity.

The 'Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): Market Insights, Epidemiology and Forecast to 2034' report provides an in-depth analysis of IC-MPGN, including historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2020 to 2034. Key highlights include approximately 7,100 diagnosed IC-MPGN cases in 2023 across 7MM, with the U.S. representing 55% of cases. The market size in the U.S. was ~USD 12 million in 2023 and is expected to grow by 2034 due to increased prevalence and emerging therapies. No approved therapies exist, with treatments currently dominated by off-label drugs. Promising emerging therapies include Novartis' iptacopan and Apellis' pegcetacoplan, both in advanced Phase III development.

DelveInsight's report on Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2034 covers historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, market size, and key companies in the US, EU5, and Japan. The market size in the US was ~USD 1,800 million in 2023, expected to increase by 2034. Key companies include Taiwan Liposome Company (TLC), Teikoku Pharma, Novartis, and others. Emerging therapies include TLC590, TPU-006, Libvatrep, and more.

The Justice Department's Consumer Protection Branch, with over 120 attorneys and staff, works to protect Americans' health, safety, and economic security by enforcing laws related to products like tobacco, food, medical devices, pharmaceuticals, and dietary supplements. The branch collaborates with various agencies, including the FDA, to hold accountable those who threaten public safety through unlawful practices, such as distributing tainted food, selling adulterated medical products, or falsifying clinical trial data. Recent actions include prosecuting opioid manufacturers and enforcing regulations on e-cigarettes to protect youth. The branch also defends FDA's medical and scientific judgments in court, ensuring that the agency's expertise is respected.

Aurobindo Pharma's subsidiary Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg, indicated for advanced RCC and STS. The drug, bioequivalent to Novartis' Votrient, has an estimated market size of $106 million for the twelve months ending October 2024. Aurobindo plans to launch the medication in Q4 FY2025.

The 'Graves' Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current pipeline landscape for Graves' Disease treatments, including detailed descriptions of drugs like Batoclimab, VRDN-001, and Linsitinib, which are in various stages of clinical development. The report highlights key companies such as Viridian Therapeutics, Immunovant Sciences, and Sling Therapeutics, and covers therapeutic assessments, pipeline development activities, and emerging trends in drug development for Graves' Disease.

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.

The 'Lupus Nephritis - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current and future prospects of Lupus Nephritis treatments. It details the pipeline landscape, including disease overview, treatment guidelines, and assessments of emerging drugs like QLG1074, ADX-097, KYV-101, CABA-201, and NKX019. The report highlights ongoing R&D efforts, key collaborations, and trends in drug development, focusing on novel approaches to improve disease management. It also covers clinical trial stages, route of administration, and molecule types, identifying unmet needs and the impact of emerging therapies.

Tendinopathy market poised for growth due to increasing prevalence, awareness, and emerging treatments by companies like MiMedx, Novartis, Ipsen, and others. Key therapies include secukinumab, PRP, MSCs, corticosteroids, nitroglycerin patches, BPC-157, collagen hydrolysate, and hyaluronic acid. Market drivers include aging populations, sports participation, biologics advancements, and early diagnosis. Barriers include high therapy costs, limited awareness in developing countries, lack of standardized protocols, and competing therapies.

Ottimo Pharma appoints David Epstein as Chair & CEO, Mehdi Shahidi as Head of Development & CMO, and James Sabry as Vice-Chair. The company focuses on Jankistomig, a PD1-VEGFR2 bi-functional antibody for cancer treatment, anticipating an IND filing in late 2025.